29 articles with SOTIO
11/12/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
11/5/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting at BIO-Europe Digital being held on October 26 - 29 , 2020 . The presentation will be made available on demand on the Bio Europe website and accessible to attendees registered for the event. The 26th annual BIO-Europe global life sciences partnering event is
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead program expected to initiate first clinical studies in 2021 Rights to BOXR platform acquired for total of $11.5 million, including $8.1 million upfront and potential $3.4 million in milestones PRAGUE, Czech Republic an
SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Radek Špíšek , chief executive officer of SOTIO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium Presentation Details: Date: A
7/16/2020Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors
SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic solid tumors. Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab. The trial is conducted in partnership with Cytune Pharma. Early results from the ongoin
SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as chief medical officer effective July 1, 2020. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist and was most recently the deputy chief medical officer of SOTIO. “Dr. Sachse has professional expertise in pharmaceutical development covering
6/25/2020Biopharma and life sciences companies provide updates on their pipelines and business plans.
SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II
SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models. The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. “SO-C101 is a highly promising modality in immuno-oncology giv
11/14/2019Companies from across the globe provide updates on their business and pipelines.
SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates
NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate under their existing license and collaboration agreement.
PPF Group, the majority owner of SOTIO, invests $6.5 million as part of MaveriX Oncology’s $20 million Series A financing round.
SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer
SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer.
Final analysis of SLU01 data confirmed promising clinical efficacy of DCVAC/LuCa active cellular immunotherapy product in patients with stage IV non-small cell lung cancer.
Senate President, Speaker of the House, Leaders of Legislation, Medicine and Advocacy Join Forces to Lead the Nation in Recognizing Prostate Cancer as a Public Health Priority and Leading Disparity
AdMeTech Foundation's 11th Annual Prostate Cancer Awareness Day at the State House Highlights Massachusetts Model of National Leadership in Public Awareness, Education and Research
Overall survival (OS) increased significantly by 13.4 months. Median Progression Free Survival (mPFS) increased by 1.8 months.
SOTIO, a biotechnology company owned by the PPF Group, announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women's Cancer.
At SOTIO, he will be responsible for clinical strategy and leading the expansion of SOTIO’s clinical-stage pipeline.